Zivo Bioscience, Inc. (NASDAQ:ZIVO) recently reported a significant acquisition of shares by a major shareholder. Mark E. Strome, through Strome Investment Management LP and Strome Group, Inc., acquired 75,000 shares of Zivo Bioscience common stock on December 26, 2024 at a price of $20.19 per share, for a total of approximately $1.51 million. The stock, which has achieved an impressive 1640% return since the beginning of the year according to InvestingPro data, it is currently trading near $20.89 and appears slightly undervalued based on fair value analysis. This transaction increases the total number of shares owned by the taxpayer to 398,683.
Additionally, the related transaction included the acquisition of 7,500 common stock purchase orders, which were executed without cost on the same date. These transactions reflect strategic moves by Strome’s entities, which have a significant stake in the company.
In other recent news, Zivo Bioscience has made significant progress in its financial operations. The Nevada-based biotech company restructured its existing debt with three creditors, issuing unsecured notes totaling approximately $277,254.38. Creditors involved include Howard Shapiro, Merger Masters Pension Fund and Financial Trading Consultants Pension Fund, which accepted the notes in exchange for settlement of outstanding debts.
These notes will be repaid over a period of 24 months starting in November 2024, with a nominal interest rate of 1.0% per annum. In the event of non-payment, creditors have the right to demand immediate payment of the unpaid principal.
In parallel with the debt restructuring, Zivo Bioscience sold 169,022 shares of its common stock to several authorized investors. The transactions took place between August and October, and the shares were sold at prices ranging from $8.34 to $16.31, an average of $10.44 per share. The sale to related parties involved 52,802 shares, sold at prices between $8.34 and $15.96, an average of $9.68 per share.
These recent developments reflect Zivo Bioscience’s strategic financial management, providing the company with additional operational flexibility.
This article was generated with the support of artificial intelligence and reviewed by an editor. See our T&C for more information.
